Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

Cladribine has been approved for the treatment of multiple sclerosis (MS) and its administration results in a long-lasting depletion of lymphocytes. As lymphopenia is known to hamper immune responses to vaccination, we evaluated the immunogenicity of the influenza vaccine in patients undergoing clad...

Full description

Bibliographic Details
Main Authors: Leoni Rolfes, Steffen Pfeuffer, Jelena Skuljec, Xia He, Chuanxin Su, Sinem-Hilal Oezalp, Marc Pawlitzki, Tobias Ruck, Melanie Korsen, Konstanze Kleinschnitz, Derya Aslan, Tim Hagenacker, Christoph Kleinschnitz, Sven G. Meuth, Refik Pul
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cells
Subjects:
multiple sclerosis
cladribine
immunization
influenza
vaccination
Online Access:https://www.mdpi.com/2073-4409/12/9/1243

Internet

https://www.mdpi.com/2073-4409/12/9/1243

Similar Items